10
Loading video...
By Maria Azzurra Volpe
Reporter
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
Scientists have created a tiny, beating piece of heart tissue from a patient's own blood cells, offering what researchers say could become a more realistic way to study dilated cardiomyopathy, a serious heart condition that often leads to heart failure.
The proof-of-concept study demonstrated that a laboratory-grown "mini-heart" made from cells taken directly from a person with dilated cardiomyopathy (DCM) was able to reproduce key features of the disease, including abnormal and irregular heartbeats.
DCM is a condition in which the heart becomes enlarged and weakened, reducing its ability to pump blood effectively throughout the body. According to the study, the disease carries a 50 percent risk of progressing to heart failure within five years, highlighting the need for better tools to understand how it develops and how it might be treated.
Read More on Health
Researchers say existing approaches, including animal models and cells grown in laboratory dishes, do not fully capture the complexity of the human heart. To address that challenge, the team turned to a patient's own cells.
Dr. Ayesha Bryant, clinical advisor of Alpas Wellness, told Newsweek that patient-derived models could provide researchers with insights that traditional models cannot because they allow scientists to study how a disease behaves within an individual's unique genetic makeup. She said that understanding those interactions may eventually support the development of more personalized treatments.
How Scientists Built a Patient-Specific Mini-Heart
The process began with blood cells collected from an individual diagnosed with DCM. Scientists reprogrammed those cells into induced pluripotent stem cells, a type of cell capable of developing into many different tissues in the body. The stem cells were then transformed into cardiomyocytes, the specialized muscle cells responsible for generating the heart's contractions.
Using those heart muscle cells, the team engineered a three-dimensional heart tissue on a chip. The tissue was capable of beating and contracting on its own, creating what researchers described as a miniature heart model.
What sets the new system apart from earlier approaches is its patient-specific design. Rather than relying on generic cells, the model was built using cells from a person living with DCM, allowing researchers to more closely recreate the biological characteristics of that individual's disease.
The scientists also incorporated tiny fluorescent beads throughout the engineered tissue. These beads acted as tracking markers, enabling researchers to monitor movement and contractions across different regions of the mini-heart during each beat. The approach provided a detailed picture of how the tissue functioned and how different areas responded as it contracted.
...
Mini-Heart Model Mirrors Key Signs of Heart Disease
To determine whether the miniature heart accurately reflected the disease, researchers created a second heart-on-a-chip using cells from a healthy individual and compared the two models side by side.
The comparison revealed differences across several important measures, including tissue structure, contraction patterns, beating behavior, calcium activity and molecular characteristics.
Most notably, the tissue derived from the DCM patient displayed abnormal and irregular beating patterns that mirrored critical features of dilated cardiomyopathy. Those findings suggest the engineered tissue was able to reproduce hallmark signs of the disease in a laboratory setting.
The team also explored how the tissues responded to outside stimulation. Both the healthy and diseased models were exposed to norepinephrine, a substance known to increase heart rate and strengthen heart contractions.
The engineered tissues reacted to the chemical stimulation, demonstrating that the lab-grown heart tissue could respond to external signals rather than functioning as a static model.
Potential for Personalized Medicine, but Early Days
Researchers say the findings show that the platform can replicate important aspects of dilated cardiomyopathy and provide insights that may not be possible with existing methods. Because the tissue is generated from an individual patient's cells, the model could eventually help scientists understand why people with the same diagnosis experience the disease differently.
"These preliminary data are exciting, especially if they are able to evolve to the point where we can predict how an individual patient’s heart disease will react to certain medications instead of using trial-and-error to find the one that fits the best," Bryant said.
The technology may also have broader implications for drug development. According to the study, the platform could help researchers investigate the biological mechanisms driving DCM, speed up the testing and evaluation of potential treatments, support preclinical drug development and identify promising therapies earlier in the research process.
The model may also complement existing research techniques, potentially reducing the need for some animal studies while supporting the development of more personalized approaches to medicine.
Still, researchers caution that the work remains in its early stages. The study involved cells from only one patient with dilated cardiomyopathy and one healthy control, making it a preliminary demonstration rather than a definitive validation of the technology.
Bryant said further research will be needed to determine whether the findings can be reproduced across larger and more diverse patient populations, as well as in other forms of heart disease.
The next step will be expanding the platform to include a much larger group of patients representing different genetic backgrounds and various forms of DCM. Researchers say that broader testing will be essential to understanding why the disease varies from person to person and to advancing the technology toward precision medicine.
"Lastly, while this research is a promising look into the future of heart disease care and personalized medicine, it is not something that should be used to guide clinical decision making and treatment recommendations at the moment," Bryant said.
Reference
Ali Mousavi et al, Patient-Derived 3D Heart-On-a-Chip Model of Dilated Cardiomyopathy With Embedded Bead-Based Mapping of Tissue Contractility, Advanced Healthcare Materials (2026). DOI: 10.1002/adhm.71464
Contact Newsweek editors on this story: Kara Dolman and Emma Lee-Sang
View 0 Comments
Submit Correction
View Editorial & AI Guidelines